SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

faithcoin

Faithcoin is trending as some users promote it with claims of "mooning" and encourage others to "buy now", while other users are calling it a scam, warning of potential rug pulls and high concentration of top holders. The coin is associated with Phantom Wallet and the Solana and Bitcoin blockchains, with some mentioning it alongside other meme coins like Pepe.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as investors discuss the company's proposed acquisition of Australian miner Larvotto Resources and its potential impact on the U.S.-Australia critical minerals strategy. Community members are speculating on the deal's implications, potential shareholder votes, and possible mentions during upcoming meetings between U.S. and Australian leaders. Bullish sentiment is fueled by the potential for significant growth in the antimony sector, with some anticipating a parabolic rise.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders weigh bullish factors like weather forecasts indicating increased heating demand and growing LNG exports against bearish elements such as ample storage levels and strong production. The community is actively discussing potential price movements as the contract roll nears, with some anticipating a volatile period. Technical analysis and weather patterns are key talking points as investors assess potential upside for the leveraged natural gas ETF.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Slap is trending as community members highlight staking opportunities and potential correlation with ETH's movements. Some users are suggesting SLAP as an alternative investment, contrasting it with other crypto projects. The discussion also includes broader market references like SPX and BTC.

MLN is the official token of Enzyme. Founded in 2017, Enzyme is the global infrastructure for tokenized finance. Enzyme provides industry leaders with a comprehensive suites of Vault-As-A-Service and Financial Instruments products to manage on-chain assets efficiently, optimize operational processes, and develop innovative financial strategies tailored to their unique goals and challenges.

Melon

$MLN is trending as traders discuss its low supply and potential for a significant price increase, drawing comparisons to other low-supply coins that have experienced substantial pumps. The community is actively speculating on upcoming price movements, with some eyeing it as the next coin to see explosive growth. Discussions also mention Enzyme's product launches and infrastructure milestones, including the Enzyme.Onyx launch targeting institutional users.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending due to positive Phase 3 ROSELLA trial data for its ovarian cancer treatment, relacorilant, showing improved progression-free survival. The community is discussing the potential for relacorilant to become a new standard of care and its implications for future revenue, with some analysts raising price targets. Despite positive news, the stock's high valuation and potential pullbacks are also being debated.

CTX is a governance token that powers and secures the Cryptex protocol. Holders of CTX can vote on protocol upgrades for TCAP as well as all future products within the Cryptex ecosystem.

Cryptex Finance

Cryptex Finance ($CTX) is trending due to notable price movement and increased trading volume, sparking discussions about its low float and potential for significant gains. The community is actively debating entry points and whether it can break through resistance levels, drawing comparisons to other altcoins like $AVT. Speculation is fueled by upcoming events related to the protocol.

China Natural Resources, Inc. is an investment holding company. The firm is primarily involved in the exploration and mining in the People’s Republic of China (PRC). It is engaged in the exploration for lead, silver, and other metals, and copper trading in the Inner Mongolia Autonomous Region of the PRC. The company was founded on December 14, 1993 and is headquartered in Hong Kong.

China Natural Resources Inc

CHNR is trending as traders discuss its potential as a lithium play after news of a planned acquisition in Zimbabwe, amplified by bullish sentiment in the lithium sector. Community members are highlighting the stock's low float and speculating about a potential short squeeze. With rising interest and zero shares available to short, traders are anticipating a significant price increase.

What is the project about? Vara Network is a substrate-based future proof smart contract platform that is fast, scalable, and makes it simple to create and deploy next-generation Web3.0 dApps Vara is the first standalone network in the Gear Protocol  Gear is a next-gen cloud infrastructure platform providing most intuitive and frictionless environment for web2 and web3 developers to build complex infrastructure solutions and disruptive dApps for any ecosystem  What makes your project unique? Vara is built upon three core concepts: The actor model, and persistent memory — two widely adopted primitives from massive computation and microservices architecture spaces  Wasm — a WebAssembly-based virtual machine that runs on all modern browsers. Proven to be faster than any alternative web2 virtual machines  Vara was created to serve as a wasm-native hub for innovative protocols that leverage parallel execution and asynchronous programming to deliver leading decentralized products in any segment  History of your project. Gear Protocol and the Vara Network were originally created by Nikolay Volf, one of the core developers of Polkadot. In 2021, he embarked on building an advanced layer 1 smart contract platform using Substrate, Polkadot's custom framework. His vision included creating a platform that enables fast and efficient execution of robust, feature-rich dApps while in a seamless development environment similar to that of Web 2.0 development. He did this by  harnessing the power of innovative technologies like Wasm, the Actor Model, and Persistent Memory. These technologies significantly enhance smart contract development and provide a seamless end-user experience and provide the foundation for the development of Vara Network.  1. Q2 2021 - Pre-Seed Round: In the second quarter of 2021, the Protocol secured its initial funding through a pre-seed round. This likely involved seeking investment from early-stage investors or venture capitalists to kickstart the development of the project.  2. Q4 2021 - Seed Round: In December 2021 raised $12 Million in Venture Round. Private investment round led by Blockchange Venture. In addition to Blockchange, other top venture capital funds participated in this round, including Three  Arrows Capital, Lemniscap, Distributed Global, LAO, Mechanism Capital, Bitscale, Spartan Group LLC, HashKey, DI Ventures, Elysium Venture Capital, Signum Capital and P2P Economy lead by Konstantin Lomashuk, along with a number of top executives of Web3 Foundation and Parity Technologies. Dr. Gavin Wood, Founder and ex-CEO of Parity Technologies and one of the key individual investors participating in this round.  3. 2022 - Intensive Scaling and Development, First Test Integrations: Throughout the year 2022, Vara was focused on two primary activities. First, the engagement in an extensive outreach process to build up the team. Second, the project advanced its technical development efforts and started working on integrating their technology with various test environments to ensure its functionality and viability.  4. Q4 2022 - Testnet Launch.   5. Q1 2023 - PoA Launch: In the first quarter of 2023, Vara achieved launch of its Proof of Authority (PoA) consensus network, which is a chain candidate for mainnet.  Current Status of Vara:  Presently, the project boasts a talented and diverse decentralized workforce, consisting of dozens of engineers and other community members  to drive the project's success.  One of the remarkable aspects of Vara is its substantial pipeline of initiatives with over 40 projects.  What’s next for your project? Current projects being researched and developed by the community:  - Intensive testing and improvement of the actor model features in the blockchain space  - Launch of the key stack of dApps in our parallel and asynchronous environment   - Development of innovative infrastructure solutions (e.g offchain zk actors including machine learning) independently and together with the segment leaders  What can your token be used for? VARA tokens maintain core utility features required for the network to operate: transaction fees staking and network security governance other: gas pools for gas reservation  Contributors to the Gear protocol are exploring the mechanics of how to distribute a portion of block rewards directly toward dApp developers

Vara Network

Vara Network is trending as the community discusses staking opportunities and potential long-term growth, despite some concerns about past dilution and current price levels. Optimistic investors highlight the project's fundamentals, its growing network, and potential for gains in the DeFi, gaming, and NFT spaces, while others express skepticism, citing concerns about tokenomics and team activity.

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending as investors discuss its low float and potential for a squeeze, with some pointing to a high short interest and others remaining skeptical due to the REIT's history of reverse splits. Community members are debating potential price targets and entry points, while also considering the company's financials and future catalysts. Overall sentiment is mixed, with some anticipating a significant upward move and others cautioning against potential risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit,' 'we,' or the 'Company') today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc...

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit,' 'we,' or the 'Company') today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class...

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.

Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.

Retail traders kept a cautious stance on Summit Therapeutics on Tuesday after Barclays initiated coverage of the biotech with an ‘Underweight’ rating and a $13 price target.&nbsp;The stock fell 4.3% to $18.12 on Tuesday and slipped another 0.4% after hours.Barclays flagged a long regulatory path, stiff competition in lung cancer, and a rival backed by a major pharma partner as key risks.The brokerage said it still sees a “high likelihood” of approval for ivonescimab, Summit’s experimental bispecific antibody, but its models suggest only modest improvements over the current standard of care.&nbsp;The note contrasted with&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/summit-therapeutics-gets-40-dollar-price-target-from-guggenheim/chwdQXARdpT">Guggenheim’s initiation</a> earlier this month at ‘Buy’ with a $40 price target, which argued the company’s late-stage trials could offer multi-fold upside if successful.The cautious call comes just days after Summit presented&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-traders-flock-to-summit-therapeutics-after-new-cancer-drug-data-shows-survival-gains/chwW19jRdqH">new follow-up data from its Phase III HARMONi trial</a> at the World Conference on Lung Cancer in Barcelona. Patients with advanced non-small cell lung cancer on ivonescimab plus chemotherapy lived a median of 16.8 months versus 14 months on chemo alone, with hazard ratios pointing to survival benefits across Western and Asian cohorts.&nbsp;Earlier results showed the study met its main goal, cutting the risk of progression or death by 48% compared with chemotherapy alone.Ivonescimab, licensed from China’s Akeso and already approved there as SMT112, has been tested in more than 2,800 patients worldwide and carries a U.S. FDA Fast Track designation.&nbsp;Summit is running additional late-stage trials, HARMONi-3 and HARMONi-7, comparing ivonescimab against Merck’s blockbuster PD-1 drug Keytruda in first-line lung cancer, with readouts expected between 2027 and 2028.On Stocktwits, retail sentiment was ‘bearish’ amid ‘low’ message volume.One user remarked that they would only consider buying Summit Therapeutics if it returned to penny-stock levels, calling it “another one added to the biotech graveyard.”<stembedurl>https://stocktwits.com/Jahlisgo/message/628908644</stembedurl>Another user said they were holding their shares following the updated brokerage reports, waiting for what they described as a future payday.<stembedurl>https://stocktwits.com/Reesh/message/628891775</stembedurl><a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Propanc Biopharma (PPCB) tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume. (Photo credit: Getty Images)

Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’

Barclays set a $13 price target, citing a long regulatory path and stiff competition in lung cancer.

Equity

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.

Retail traders turned their attention to Summit Therapeutics late Sunday after the company released new follow-up data from its Phase III HARMONi trial. The study is testing ivonescimab, an experimental cancer drug, together with chemotherapy in patients with advanced non-small cell lung cancer.The trial focused on people whose tumors carried Estimated Glomerular Filtration Rate (EGFR) mutations and who had already failed a third-generation EGFR therapy. In this group, past attempts with PD-1 drugs had not delivered survival gains.In fresh results presented at the World Conference on Lung Cancer in Barcelona, patients on ivonescimab plus chemotherapy lived longer on average than those on chemotherapy alone.&nbsp;The overall survival hazard ratio&nbsp;was 0.78,&nbsp;indicating an improvement from the earlier analysis. Median survival was 16.8 months with the drug compared to 14.0 months with chemotherapy.Among Western patients,&nbsp;the median overall survival&nbsp;was 17 months with ivonescimab versus 14 months for the placebo. In North America specifically, median overall survival had not yet been reached in the ivonescimab arm compared with 14 months on chemotherapy alone.&nbsp;Median survival in Asian patients was 16.7 months for ivonescimab versus 14 months for chemotherapy.The primary analysis, conducted in April, had shown a positive trend in overall survival but did not meet statistical significance. The company noted that&nbsp;the median follow-up for Western patients was shorter than their median overall survival at that time.Earlier results had already&nbsp;demonstrated that the trial met its main goal. Patients on ivonescimab plus chemotherapy were 48% less likely to see their cancer worsen or to die compared with those on chemotherapy alone.The treatment also produced better responses: 45% of patients saw their tumors shrink versus 34% on chemotherapy, and those responses lasted longer, with a median of 7.6 months compared with 4.2 months.Safety data showed the combination was generally manageable and consistent with prior studies.&nbsp;Grade 3 or higher treatment-related adverse events occurred in 50% of ivonescimab patients versus 42.2% in the chemotherapy arm. Discontinuations due to adverse events were 7.3% versus 5%, and treatment-related deaths were reported in 1.8% and 2.3% of patients, respectively. The most common events were anemia and reduced blood counts, with less than 1% of ivonescimab patients experiencing severe hemorrhage.Ivonescimab, also known as SMT112 outside China, is a first-in-class bispecific antibody targeting both PD-1 and Vascular Endothelial Growth Factor (VEGF).&nbsp;It was engineered by China’s Akeso and has been tested in more than 2,800 patients globally. The drug is already approved in China and has&nbsp;a U.S. FDA Fast Track designation in the HARMONi trial setting.On Stocktwits, retail sentiment for Summit was ‘extremely bullish’ amid ‘extremely high’ message volume.One retail user said that long-term investors in Summit had grown used to the stock falling even on positive news, but pointed out shares are still up nearly 700% over the past five years.<stembedurl>https://stocktwits.com/EB2224/message/627780145</stembedurl>Another user noted that while the day had been volatile, “the markets don’t lie” and suggested Summit CEO Robert Duggan might have more to reveal, adding that he has a reputation for frustrating short sellers. The user speculated the stock could hit $30 by the end of the day.<stembedurl>https://stocktwits.com/BooEmmy/message/627780010</stembedurl><a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 45.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Summit’s stock (SMMT) has risen 45.6% so far in 2025. (Photo credit: Getty Images)

Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains

The updated Phase III HARMONi trial showed Western patients on ivonescimab lived a median 17 months versus 14 months on chemotherapy.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.17	--	--	N/A
Q2 '25	-$0.09	-$0.76	-736.88%	MISSED
Q1 '25	-$0.09	-$0.09	3.25%	BEAT
Q4 '24	-$0.08	-$0.08	1.20%	BEAT
Q3 '24	-$0.07	-$0.05	25.10%	BEAT

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest SMMT News

SMMTSummit Therapeutics Inc